Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51345 | 0.94 | NR1I2 (0.43) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL278177 | 0.94 | NR1I2 (0.42) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3365767 | 0.92 | NR1I2 (0.46) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL4498396 | 0.91 | NR1I2 (0.45) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL862852 | 0.90 | KCNH2 (0.40) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL15949105 | 0.90 | KCNH2 (0.39) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL14900142 | 0.88 | NR1I2 (0.44) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13531015 | 0.88 | NR1I2 (0.43) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL863087 | 0.88 | KCNH2 (0.38) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL51278 | 0.87 | KCNH2 (0.48) | NR1I2KCNH2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127010-B2 | Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | claimed |
| EP-2585438-B1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R & D IRELAND (IE) | 2014-08-20 | — | — | EP | claimed |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | JANSSEN R&D IRELAND (IL) | 2013-04-25 | — | — | US | claimed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2099804-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | JANSSEN SCIENCES IRELAND UC (IE) | 2015-11-19 | — | — | US | disclosed |
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008089027-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089027-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074715-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885KCNH2 3808/4885CYP3A4 214/4885 |
| US-20130102777-A1 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID | HTR3C, CHAT, KDM5C | NR1I2 2234/4885KCNH2 112/4885CYP3A4 196/4885 |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | ZC3HAV1, ODC1, MED1 | NR1I2 343/4885KCNH2 1814/4885CYP3A4 2107/4885 |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | NR1I2 189/4885KCNH2 3808/4885CYP3A4 214/4885 |
| US-20150329482-A1 | Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid | HTR2A, HTR3C, HTR6 | NR1I2 2347/4885KCNH2 153/4885CYP3A4 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.